Carlos Eduardo Gonzales Matos

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, The Lancet.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, Lancet.